Zhaoning Xu1,2, Pingping Li2, Chi Zhang3, Dedong Ma4. 1. Institute of Respiratory Monitoring and Support, Shandong University, Jinan, 250012, Shandong, China. 2. School of Nursing and Rehabilitation, Shandong University, Jinan, 250012, Shandong, China. 3. School of Stomatology, Shandong University, Jinan, 250012, Shandong, China. 4. Department of Pulmonary and Critical Care Medicine, Qilu Hospital, Shandong University, Jinan, 250012, Shandong, China. ma@qiluhuxi.com.
Abstract
PURPOSE: Heated humidified high-flow nasal cannula (HFNC) oxygen therapy is one of the most important oxygen therapy methods, which are commonly applied to relieve dyspnea in advanced cancer patients. Our study aims to observe the efficacy and safety of HFNC oxygen therapy on dyspnea patients with advanced cancer and explore the clinical application. METHODS: Sixty subjects with advanced cancer requiring oxygen therapy from a grade 3, class A hospital in China were recruited and randomized (1:1) to traditional nasal catheter oxygen therapy or HFNC. Primary outcomes were dyspnea, oral dryness, and sleep condition, which were recorded after 72-h treatment. Secondary outcomes were heart rate (HR), respiration rate (RR), SpO2, PaO2, and PaCO2, which were recorded after 2, 6, 24, and 72 h treatment. RESULTS: Seventy-two hours after treatment, there were significant improvements in all primary outcomes (P < 0.001). PaO2 and RR were statistically changed 2 h after HFNC treatment (P < 0.001). PaCO2 and HR were statistically changed 24 h after HFNC treatment (P < 0.001). CONCLUSION: HFNC oxygen therapy has good effect, high safety, and is easy to be accepted by dyspnea patients with advanced cancer. It can be used as the first choice of oxygen therapy for these patients and has broad clinical prospects. TRIAL REGISTRATION: This work was retrospectively registered in the Chinese Clinical Trials Registry (ChiCTR2100049582) on August 4, 2021.
PURPOSE: Heated humidified high-flow nasal cannula (HFNC) oxygen therapy is one of the most important oxygen therapy methods, which are commonly applied to relieve dyspnea in advanced cancer patients. Our study aims to observe the efficacy and safety of HFNC oxygen therapy on dyspnea patients with advanced cancer and explore the clinical application. METHODS: Sixty subjects with advanced cancer requiring oxygen therapy from a grade 3, class A hospital in China were recruited and randomized (1:1) to traditional nasal catheter oxygen therapy or HFNC. Primary outcomes were dyspnea, oral dryness, and sleep condition, which were recorded after 72-h treatment. Secondary outcomes were heart rate (HR), respiration rate (RR), SpO2, PaO2, and PaCO2, which were recorded after 2, 6, 24, and 72 h treatment. RESULTS: Seventy-two hours after treatment, there were significant improvements in all primary outcomes (P < 0.001). PaO2 and RR were statistically changed 2 h after HFNC treatment (P < 0.001). PaCO2 and HR were statistically changed 24 h after HFNC treatment (P < 0.001). CONCLUSION: HFNC oxygen therapy has good effect, high safety, and is easy to be accepted by dyspnea patients with advanced cancer. It can be used as the first choice of oxygen therapy for these patients and has broad clinical prospects. TRIAL REGISTRATION: This work was retrospectively registered in the Chinese Clinical Trials Registry (ChiCTR2100049582) on August 4, 2021.
Authors: Marco Maltoni; Augusto Caraceni; Cinzia Brunelli; Bert Broeckaert; Nicholas Christakis; Steffen Eychmueller; Paul Glare; Maria Nabal; Antonio Viganò; Philip Larkin; Franco De Conno; Geoffrey Hanks; Stein Kaasa Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: Karl A Lorenz; Joanne Lynn; Sydney M Dy; Lisa R Shugarman; Anne Wilkinson; Richard A Mularski; Sally C Morton; Ronda G Hughes; Lara K Hilton; Margaret Maglione; Shannon L Rhodes; Cony Rolon; Virginia C Sun; Paul G Shekelle Journal: Ann Intern Med Date: 2008-01-15 Impact factor: 25.391